Detailed explanation of the efficacy and role of pirfenidone/Axri

Pirfenidone/Pirfenidone is a new drug mainly used to treat idiopathic pulmonary fibrosis (IPF). Its core functions include anti-inflammatory, antioxidant and anti-fibrosis. Studies have shown that pirfenidone can significantly improve the lung function of IPF patients and effectively reduce the frequency of acute exacerbations.

Although the exact mechanism of action of pirfenidone is not fully understood, there is evidence that its antioxidant properties contribute significantly to its anti-inflammatory and anti-fibrotic effects. Specifically, pirfenidone significantly reduces the production of transforming growth factor-β1 (TGF-β1). TGF-β1 is an important pro-fibrotic and pro-inflammatory cytokine closely related to the development of IPF. By inhibiting TGF-β1, pirfenidone can effectively prevent the differentiation of lung fibroblasts into myofibroblasts, thereby reducing the synthesis of excess collagen and extracellular matrix and slowing down the fibrosis process.

Further research found that pirfenidone can also downregulate the levels of a variety of pro-inflammatory cytokines, including tumor necrosis factorα (TNF-α), interleukin-1 (IL-1), IL-6, interferon-γ (IFN-γ) and platelet-derived growth factor (PDGF). In animal experiments, pirfenidone has been shown to promote the production of the anti-inflammatory cytokine IL-10 and effectively inhibit the accumulation of a variety of inflammatory cells (such as lymphocytes, macrophages, and neutrophils). At the same time, it can also improve bleomycin-induced pulmonary vascular permeability, further demonstrating its potential in reducing inflammatory responses.

In vitro experiments show that pirfenidone exerts its antioxidant effect by scavenging reactive oxygen species (ROS) and inhibiting lipid peroxidation, thereby reducing cell damage caused by oxidative stress. This property makes pirfenidone not only able to alleviate existing pathological conditions, but may also play a preventive role in the progression of the disease.